SHAREHOLDERS' EQUITY | 8. SHAREHOLDERS’ EQUITY Stock-based Compensation As of December 31, 2022 and 2021, the Company had issued and outstanding stock options of 3,910,000 and 2,180,000, respectively, that were issued under its 10% Rolling Stock Option Plan, as amended, and restated (the “2011 Plan”) and 250,000 and nil, respectively, that were issued under its 2022 Equity Incentive Plan (the “2022 Plan”). The 2011 Plan was replaced in 2022 by the 2022 Plan, and as such, no additional stock options can be granted under the 2011 Plan. Under the 2011 Plan, our Board of Directors could from time-to-time grant stock options to eligible directors, officers, employees, and consultants. The maximum term of any stock option grant under the 2011 Plan was 10 years. Under the 2022 Plan, as approved by our shareholders at the annual meeting of shareholders on August 23, 2022, our Board of Directors is authorized to grant stock options, stock appreciation rights, restricted stock units, performance stock units and other cash and share-based awards to eligible directors, officers, employees, or consultants up to a maximum of 17,236,689 common shares. The maximum term of any grant under the 2022 Plan is 10 years. The Company estimates the fair value of its stock option grants using the Black-Scholes option valuation model and the closing price of our common shares on the grant date. The significant assumptions used to estimate the fair value of the 2,080,000 and 855,000 stock option awards granted during the years ended December 31, 2022 and 2021, respectively, were as follows: Year Ended December 31, 2022 2021 Risk-free interest rate 1.71-4.18 % 1.69 % Expected volatility 135 - 144 % 146 % Expected dividend yield Nil Nil Expected term in years 8 8 The following table summarizes our stock option activity for the years ended December 31, 2022 and 2021: Year Ended December 31, 2022 2021 Weighted Weighted Average Average Number of Stock Exercise Number of Stock Exercise Options Price Options Price Outstanding, beginning of period 2,180,000 $ 1.18 3,100,000 $ 0.28 Granted 2,080,000 $ 1.29 855,000 $ 2.25 Exercised (1) (100,000) $ 0.25 (1,775,000) $ 0.13 Outstanding, end of period 4,160,000 $ 1.26 2,180,000 $ 1.18 Exercisable, end of period 2,932,500 $ 1.28 1,377,500 $ 0.94 Non-vested, end of period 1,227,500 $ 1.20 802,500 $ 1.59 (1) The 100,000 and 1,775,000 of stock options exercised during the years ended December 31, 2022 and 2021, respectively, resulted in 49,062 and 1,763,200 common shares being issued on a net settlement basis pursuant to the terms of the 2011 Plan. Stock-based compensation expense is included in corporate administration expenses within the Company’s consolidated statements of operations. For the years ended December 31, 2022 and 2021, the Company recognized compensation expense related to stock option awards of $2,920 and $1,536, respectively. As of December 31, 2022, there was approximately $173 of total unrecognized compensation cost related to the 1,227,500 unvested stock options that is expected to be recognized over a weighted-average remaining period of approximately 1.8 years. Weighted Average Remaining As of December 31, 2022: Intrinsic Value Life (Years) Stock options outstanding $ 168 6.8 Stock options exercisable $ 168 5.7 Stock options non-vested $ — 9.2 The intrinsic value of stock options exercised during the years ended December 31, 2022 and 2021 was $24 and $2,985, respectively. The weighted-average grant-date fair value of options granted during the years ended December 31, 2022 and 2021 was $1.29 and $2.25, respectively. See Note 13 for a discussion of stock options granted subsequent to December 31, 2022. Rights Offering During December 2021, the Company completed a rights offering for gross proceeds of approximately $25,400 in which each holder of the Company’s common shares as of the close of business on the record date of October 19, 2021 was eligible to participate. Terms of the rights offering included the issuance of one subscription right for each common share owned by each holder on the record date with each subscription right entitling the holder to purchase one common share of the Company at a subscription price of $0.24 per share (the “basic subscription privilege”). If any holder exercised its basic subscription privilege in full, the holder could also exercise an oversubscription privilege to purchase additional common shares for which were unsubscribed at the expiration of the rights offering, subject to availability and pro rata allocation of shares among persons exercising the oversubscription privilege. The rights offering resulted in the issuance of 105,808,444 Common Shares of the Company. The net proceeds from the rights offering are being used for the permitting, licensing, engineering, construction and operation of the rare earth separation and processing Demonstration Plant near the Company’s Bear Lodge REE Project and other general corporate purposes, with a portion used for the repayment of outstanding indebtedness, in the principal amount of $1,000, which repayment was completed in December 2021. The previously discussed $21,900 financial award from the DoE for the Demonstration Plant is expected to fund approximately one |